XH001 Combination With Immunocheckpoint Inhibitor and Chemotherapy for Patients With Resected Pancreatic Cancer
This is a single-center, open label, single-arm, investigator-initiated study to evaluate the efficacy and safety of XH001 (neoantigen cancer vaccine) sequential combination with immunocheckpoint inhibitor and chemotherapy in pancreatic cancer patients following surgical resection.
Pancreatic Cancer
BIOLOGICAL: XH001|DRUG: Ipilimumab Injection|DRUG: Sintilimab injection|DRUG: Chemotherapy
DFS, disease-free survival (DFS), up to 36 months|DFS rate, disease-free survival rate, up to 36 months|MFS, metastasis-free survival (MFS), up to 36 months|OS, overall survival (OS), From date of recruitment until the date of first documented date of death from any cause, assessed up to 36 months
Elispot, Antigen-specific T-cell responses in peripheral blood, up to 36 months|Adverse Event, Incidence and severity of adverse events (AEs), clinically significant abnormal changes in laboratory tests or other examinations (based on the Criteria for the Evaluation of Adverse Events \[CTCAE\] v5.0)., up to 36 months|ctDNA, Changes of ctDNA compared to baseline, up to 36 months|CA19-9, Changes of CA19-9 compared to baseline, up to 36 months
This is a single-center, open label, single-arm, investigator-initiated study to evaluate the efficacy and safety of XH001 (neoantigen cancer vaccine) sequential combination with immunocheckpoint inhibitor and chemotherapy in pancreatic cancer patients following surgical resection.